• Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.

  Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J.
  Sci Transl Med. 2022 Mar 16. 636(14).

• Photon Counting CT and Radiomic Analysis Enables Differentiation of Tumors Based on Lymphocyte Burden.

  Allphin AJ, Mowery YM, Lafata KJ, Clark DP, Bassil AM, Castillo R, Odhiambo D, Holbrook MD, Ghaghada KB, Badea CT.
  Tomography. 2022 Mar 10. 2(8).

• Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.

  Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BY, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT.
  Sci Transl Med. 2022 Mar 09. 635(14).

• Developmentally distinct CD4⁺ T_reg lineages shape the CD8⁺ T cell response to acute Listeria infection.

  Dolina JS, Lee J, Moore EL, Hope JL, Gracias DT, Matsutani T, Chawla A, Greenbaum JA, Linden J, Schoenberger SP.
  Proc Natl Acad Sci U S A. 2022 Mar 08. 10(119).

• Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

  Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M.
  Blood. 2022 Mar 03. 9(139).

• Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection.

  Heft Neal ME, Smith JD, Birkeland AC, Haring CT, Chinn SB, Shuman AG, Casper KA, Malloy KM, Stucken CL, Mclean SA, Rosko AJ, Mierzwa ML, Shah J, Schonewolf C, Swiecicki PL, Worden FP, Wolf GT, Bradford CR, Prince MEP, Brenner JC, Spector ME.
  Otolaryngol Head Neck Surg. 2022 Mar. 3(166).

• Practical and robust test for comparing binomial proportions in the randomized phase II setting.

  Attwood K, Park S, Hutson AD.
  Pharm Stat. 2022 Mar. 2(21).

• MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.

  Luan Z, Morimoto Y, Fushimi A, Yamashita N, Suo W, Bhattacharya A, Hagiwara M, Jin C, Kufe D.
  Carcinogenesis. 2022 Feb 11. 1(43).

• IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.

  Song NY, Li X, Ma B, Willette-Brown J, Zhu F, Jiang C, Su L, Shetty J, Zhao Y, Shi G, Banerjee S, Wu X, Tran B, Nussinov R, Karin M, Hu Y.
  Proc Natl Acad Sci U S A. 2022 Feb 08. 6(119).

• Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy.

  Franiak-Pietryga I, Miyauchi S, Kim SS, Sanders PD, Sumner W, Zhang L, Mundt AJ, Califano JA, Sharabi AB.
  Int J Radiat Oncol Biol Phys. 2022 Feb 01. 2(112).

• Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

  Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Turner JBM, Gigliotti PJ, Kraskauskiene V, Shende M, Idowu MO, Puchalapalli M, Hu B, Litovchick L, Katsuta E, Takabe K, Farrell NP, Koblinski JE.
  Mol Cancer Ther. 2022 Feb. 2(21).

• TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.

  Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR.
  Immunity. 2022 Jan 11. 1(55).

• Regulation of antitumor immunity by inflammation-induced epigenetic alterations.

  Karin M, Shalapour S.
  Cell Mol Immunol. 2022 Jan. 1(19).

• Short-course neoadjuvant in situ vaccination for murine melanoma.

  Aiken TJ, Komjathy D, Rodriguez M, Stuckwisch A, Feils A, Subbotin V, Birstler J, Gillies SD, Rakhmilevich AL, Erbe AK, Sondel PM.
  J Immunother Cancer. 2022 Jan. 1(10).

• Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.

  Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R.
  J Immunother Cancer. 2022 Jan. 1(10).

• Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.

  Makino K, Long MD, Kajihara R, Matsueda S, Oba T, Kanehira K, Liu S, Ito F.
  J Immunother Cancer. 2022 Jan. 1(10).

• Case-cohort design in hematopoietic cell transplant studies.

  Cai J, Kim S.
  Bone Marrow Transplant. 2022 Jan. 1(57).

• Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.

  Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR.
  PLoS One. 2022. 2(17).

• Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.

  Rangel R, Pickering CR, Sikora AG, Spiotto MT.
  Front Immunol. 2022. (13).

• Tcf-1 protects anti-tumor TCR-engineered CD8⁺ T-cells from GzmB mediated self-destruction.

  Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K.
  Cancer Immunol Immunother. 2022 Apr 23. ().

• Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.

  Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN, Gutkind JS.
  Cells. 2022 Apr 18. 8(11).

• Understanding Drug Sensitivity and Tackling Resistance in Cancer.

  Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD.
  Cancer Res. 2022 Apr 15. 8(82).

• CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.

  Bernareggi D, Xie Q, Prager BC, Yun J, Cruz LS, Pham TV, Kim W, Lee X, Coffey M, Zalfa C, Azmoon P, Zhu H, Tamayo P, Rich JN, Kaufman DS.
  Nat Commun. 2022 Apr 07. 1(13).

• Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.

  Altorki NK, Borczuk AC, Harrison S, Groner LK, Bhinder B, Mittal V, Elemento O, McGraw TE.
  Cell Rep. 2022 Apr 05. 1(39).

• MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.

  Bhattacharya A, Fushimi A, Yamashita N, Hagiwara M, Morimoto Y, Rajabi H, Long MD, Abdulla M, Ahmad R, Street K, Liu S, Liu T, Kufe D.
  Mol Cancer Res. 2022 Apr 01. 4(20).

• Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs.

  Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, Ramms DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS.
  Mol Cancer Ther. 2022 Apr 01. 4(21).

• PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

  Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB.
  Nat Med. 2022 Apr. 4(28).

• UACA locus is associated with breast cancer chemoresistance and survival.

  Zhu Q, Schultz E, Long J, Roh JM, Valice E, Laurent CA, Radimer KH, Yan L, Ergas IJ, Davis W, Ranatunga D, Gandhi S, Kwan ML, Bao PP, Zheng W, Shu XO, Ambrosone C, Yao S, Kushi LH.
  NPJ Breast Cancer. 2022 Mar 23. 1(8).

• A programmable encapsulation system improves delivery of therapeutic bacteria in mice.

  Harimoto T, Hahn J, Chen YY, Im J, Zhang J, Hou N, Li F, Coker C, Gray K, Harr N, Chowdhury S, Pu K, Nimura C, Arpaia N, Leong KW, Danino T.
  Nat Biotechnol. 2022 Mar 17. ().

• Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells.

  Kirkemo LL, Elledge SK, Yang J, Byrnes JR, Glasgow JE, Blelloch R, Wells JA.
  Elife. 2022 Mar 08. (11).

• Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.

  von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS, Khan S, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Xie Y, Li QZ, Wakeland EK, Gerber DE.
  Cancers (Basel). 2022 Mar 04. 5(14).

• Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions.

  Koşaloğlu-Yalçın Z, Lee J, Greenbaum J, Schoenberger SP, Miller A, Kim YJ, Sette A, Nielsen M, Peters B.
  iScience. 2022 Feb 18. 2(25).

• The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.

  Meier JA, Savoldo B, Grover NS.
  J Pers Med. 2022 Feb 01. 2(12).

• Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis.

  Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL.
  Blood Adv. 2022 Jan 25. 2(6).

• Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.

  von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE.
  Cancer Immunol Immunother. 2022 Jan 24. ().

• Interleukin-12 as an in situ cancer vaccine component: a review.

  Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL.
  Cancer Immunol Immunother. 2022 Jan 13. ().

• Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery.

  Chen ST, Park MD, Del Valle DM, Buckup M, Tabachnikova A, Simons NW, Mouskas K, Lee B, Geanon D, D'Souza D, Dawson T, Marvin R, Nie K, Thompson RC, Zhao Z, LeBerichel J, Chang C, Jamal H, Chaddha U, Mathews K, Acquah S, Brown SA, Reiss M, Harkin T, Feldmann M, Powell CA, Hook JL, Kim-Schulze S, Rahman AH, Brown BD, Beckmann ND, Gnjatic S, Kenigsberg E, Charney AW, Merad M.
  bioRxiv. 2022 Jan 12. ().